LA JOLLA PHARMACEUTICAL CO Form 8-K June 03, 2004

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 2, 2004

La Jolla Pharmaceutical Company

(Exact Name of Registrant as Specified in Charter) Delaware 0-24274 33-0361285 (State or Other Jurisdiction (Commission (IRS Employer File Number) Identification No.) of Incorporation) 6455 Nancy Ridge Drive, San Diego, California 92121 (Address of Principal Executive Offices) (Zip Code) Registrant s telephone number, including area (858) 452-6600 code: N/A (Former Name or Former Address, if Changed Since Last Report)

TABLE OF CONTENTS

Item 5. Other Events and Required FD Disclosure.

<u>Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.</u>

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

Table of Contents

Item 5. Other Events and Required FD Disclosure.

On June 2, 2004, the Company issued a press release announcing that Steven Engle, the Company s Chief Executive Officer, would present at the Pacific Growth Equities Life Sciences Growth Conference on June 9, 2004. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits. The following exhibits are filed with this report on Form 8-K:

Exhibit Number	Description of Exhibit	
99.1	Press Release	

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LA JOLLA PHARMACEUTICAL COMPANY

Date: June 3, 2004 By: /s/ Gail A. Sloan

Gail A. Sloan

Vice President of Finance and Controller

Table of Contents

EXHIBIT INDEX

Exhibit Number	Description of Exhibit	
99.1	Press Release	